RBC Europe’s AVEO Pharmaceuticals, Inc. AVEO Stock Holding History

RBC Europe’s Portfolio AVEO Stock Details AVEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-25	Closed	-$841	–	1163
2018 Q3	$841	Hold	25	–	–	﹤0.01%	1075
2018 Q2	$574	Hold	25	–	–	﹤0.01%	1102
2018 Q1	$737	Hold	25	–	–	﹤0.01%	1074
2017 Q4	$709	Hold	25	–	–	﹤0.01%	1088
2017 Q3	$927	Buy	+25	New	+$773	﹤0.01%	1080

Other funds holding AVEO

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

GIM

Granahan Investment Management Waltham, Massachusetts $2.07B AUM 56.45% 1-Year Est. Return

6CM

683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

RBC Europe's AVEO Position: Q4 2018 in Review

RBC Europe sold out of AVEO Pharmaceuticals, Inc. (AVEO) in Q4 2018, closing a stake of 25 shares — an estimated $841 sold.

RBC Europe first reported a position in AVEO in Q3 2017 and held it in 5 quarters. The position peaked at $927 in Q3 2017. 99 funds tracked by Wall St. Rank hold AVEO as of Q4 2018.

RBC Europe reported no remaining AVEO Pharmaceuticals, Inc. position as of Q4 2018 after selling out during the quarter.
RBC Europe sold 25 AVEO Pharmaceuticals, Inc. shares in Q4 2018, an estimated $841.
RBC Europe first reported a position in AVEO Pharmaceuticals, Inc. in Q3 2017 and held it in 5 quarters.
RBC Europe's AVEO Pharmaceuticals, Inc. position peaked at $927 in Q3 2017.
99 funds tracked by Wall St. Rank held AVEO Pharmaceuticals, Inc. as of Q4 2018.

Based on RBC Europe's 13F filing for Q4 2018, filed 9 Nov 2023.